Search

The article discusses the development and validation of a new scoring system called the Atopic Dermatitis Activity Score 7 (ADAS7) for assessing disease activity in patients with atopic dermatitis (AD). The ADAS7 score combines clinical signs, patient-reported symptoms, and quality of life measures. The study found that ADAS7 correlated well with the existing scoring system, SCORing Atopic Dermatitis (SCORAD), and was able to identify patients with controlled AD, non-controlled AD with continuously severe disease, and non-controlled AD with active (fluctuating) disease. The limitations of the study include a small sample size and potential selection bias due to loss-to-follow-up. The authors suggest that ADAS7 can be a useful tool for discussing long-term disease control and treatment strategies with patients. [Extracted from the article]

We report a case of congenital multisystem Langerhans cell histiocytosis with cutaneous and hematopoietic involvement. After the failure of first‐line (vinblastine and prednisolone) and second‐line (vincristine and cytarabine) therapies, treatment with cobimetinib, a mitogen‐activated protein kinase (MEK) inhibitor, led to the remission of disease and a sustained response after 11 months of ongoing treatment. Protein kinase inhibitors targeting BRAF or MEK could represent a promising future therapeutic option, also in children with LCH. [ABSTRACT FROM AUTHOR]

A real-life observational study was conducted to evaluate the effectiveness and safety of tralokinumab, a monoclonal antibody, in adolescents with severe atopic dermatitis (AD). The study included 14 adolescents who had failed previous treatments and were treated with tralokinumab for 12 to 16 weeks. The primary outcome was improvement in clinical scores, specifically the Eczema Area and Severity Index (EASI) and the Peak Pruritus Numerical Rating Scale (PP-NRS). The study found that tralokinumab was effective in improving EASI and PP-NRS scores in most patients, with 28.6% achieving an EASI 75 and 42.8% experiencing a four-point or higher reduction in PP-NRS. The most common adverse events were flare of AD and injection-site reactions. The study concluded that tralokinumab is effective and well-tolerated in adolescents with severe AD, but longer-term studies are needed. [Extracted from the article]

Granuloma annulare (GA) is a rare inflammatory granulomatous disorder and its subcutaneous forms are even more uncommon. Only a few familial cases of this condition have been reported in the literature. We report a case of familial subcutaneous GA in two siblings during childhood., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Kul et al.)

There is an increasing interest in the use of facial dermal filler injections, such as hyaluronic acid, for esthetic and rejuvenation purposes. However, their use is associated with a potential risk of complications. We report the case of a woman in her thirties, with rapidly evolving facial skin necrosis following accidental intravascular injection of hyaluronic acid and/or extravascular compression. The necrosis worsened despite early repeated local injections of hyaluronidase. However, rapid and favorable clinical evolution was observed after the patient was treated for seven consecutive days with intravenous infusion of dinoprostone (a prostaglandin E2)., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Gaudissart et al.)

Bullous pemphigoid (BP) is an acquired auto-immune blistering disease, which is uncommon during childhood. Infantile BP usually has a good prognosis with rare recurrence and the suspected triggers are vaccines or viruses. We report the case of a three-month-old infant girl who presented with BP a week after a SARS-CoV-2 infection and three weeks after the first doses of polio, tetanus, diphtheria, pertussis, Haemophilus influenzae type-b, hepatitis, and pneumococcus vaccinations. Both triggers (infection and vaccination) could be implicated as a slight recurrence was observed after the second doses of vaccines. Rapid clinical resolution was obtained with topical corticosteroids., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Moens et al.)